SEC Form 4 · accession 0000899243-17-011883
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rodger Novak
Officer — Chief Executive Officer · Director
Period of report
Apr 19, 2017
Accepted (ET)
May 4, 2017 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | May 2, 2017 | M | 15,924 | $1.81 | A | 1,230,929 | D | |
| Common SharesF2 | May 2, 2017 | S | 15,924 | $16.5308 | D | 1,215,005 | D | |
| Common Shares | May 3, 2017 | M | 20,269 | $1.81 | A | 1,235,274 | D | |
| Common SharesF3 | May 3, 2017 | S | 19,247 | $16.0536 | D | 1,216,027 | D | |
| Common SharesF4 | May 3, 2017 | S | 1,022 | $16.6366 | D | 1,215,005 | D | |
| Common Shares | May 4, 2017 | M | 13,191 | $1.81 | A | 1,229,196 | D | |
| Common SharesF5 | May 4, 2017 | S | 13,191 | $16.3718 | D | 1,215,005 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F6 | $1.81 | May 2, 2017 | M | 50,000 | D | — | Sep 10, 2025 | Common Shares | 50,000 | 202,169 | D |
| Stock Options (Right to Buy)F6 | $1.81 | May 3, 2017 | M | 20,269 | D | — | Sep 10, 2025 | Common Shares | 20,269 | 181,900 | D |
| Stock Options (Right to Buy)F6 | $1.81 | May 4, 2017 | M | 13,191 | D | — | Sep 10, 2025 | Common Shares | 13,191 | 168,709 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.45, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.51 to $16.84, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.78, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F6This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter.